Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
14 janv. 2016 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...
Geron Announces December Conference Presentation Webcasts
30 nov. 2015 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present...
Geron to Present At the Stifel Healthcare Conference
10 nov. 2015 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at...
Geron Corporation Reports Third Quarter 2015 Financial Results
05 nov. 2015 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter ended September 30, 2015. For the third quarter of...
Geron Announces Presentations at American Society of Hematology Annual Meeting
05 nov. 2015 09h03 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that three abstracts describing clinical and non-clinical data on imetelstat have been...
Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
16 sept. 2015 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in...